Evidence map›Paper›PMID 36156738›Full record

SynthesisEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2023

Update on the efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis.

Shahid Miangul, Timothy Oluwaremi, Joe El Haddad, Maamoun Adra, Nathan Pinnawala, Hayato Nakanishi, Reem H Matar, Christian A Than, Thomas M Stewart

Erratum issuedOpen access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Tranexamic acid in hip fracture repair surgery: safe and effective?Blood transfusion = Trasfusione del sangue · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Is tranexamic acid safe for the hip joint?Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

Shahid MiangulSt George's University of London, London, SW17 0RE, UK. shahster96@gmail.com.ORCID http://orcid.org/0000-0002-8236-4902
Timothy OluwaremiSt George's University of London, London, SW17 0RE, UK.
Joe El HaddadSt George's University of London, London, SW17 0RE, UK.
Maamoun AdraSt George's University of London, London, SW17 0RE, UK.
Nathan PinnawalaSt George's University of London, London, SW17 0RE, UK.
Hayato NakanishiSt George's University of London, London, SW17 0RE, UK.
Reem H MatarSt George's University of London, London, SW17 0RE, UK.
Christian A ThanSt George's University of London, London, SW17 0RE, UK.
Thomas M StewartDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
St George's, University of London · GBMayo Clinic in Arizona · USThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of this meta-analysis was to assess the safety and efficacy of tranexamic acid (TXA) in the management of hip fracture surgeries in comparison with placebo.

methodsA systematic search was conducted from August 6, 2021. Eligible studies included randomized clinical trials and prospective studies comparing the use of intravenous TXA in patients treated for hip fractures, in comparison with placebo. Review Manager was used for the meta-analysis.

resultsEighteen prospective studies including 14 RCTs met the eligibility criteria. The results favored the TXA group in the quantity of total blood loss (MD =  - 196.91 mL, 95% CI - 247.59, - 146.23, I

conclusionAdministration of intravenous TXA appears to reduce blood loss, rate of blood transfusions and pose no increased risk of thromboembolic events. Therefore, TXA should be considered by physicians when managing hip fracture patients.

Indexed as

Antifibrinolytic AgentsHip FracturesThromboembolismTranexamic AcidAdministration, IntravenousBlood Loss, SurgicalHumansProspective StudiesAntifibrinolytic AgentsTranexamic AcidBlood lossHip fracture surgeryMeta-analysisTranexamic acidTXA

Identifiers

PMID36156738
PMCPMC10275812
OpenAlexW4297224478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.